Clinical trials all over the world are showing positive results when treating COVID-19 patients suffering from ARDS with MSCs.
The worldwide race to develop effective therapies for complications from COVID-19 infection are ongoing. Patients with particularly severe responses are often diagnosed with acute respiratory distress syndrome (ARDS).
COVID-19 patients dependent on ventilators showed promising results when treated with new drug in New York’s Mt. Sinai hospital.
The U.S Food and Drug Administration approved Mesoblast’s Investigational New Drug (IND) application to treat patients with COVID-19−related Acute Respiratory Distress Syndrome (ARDS) using remestemcel-L, an intravenous (IV) infusion of allogeneic mesenchymal stem cells (MSCs).
Researchers continue to build on success of treating AML patients with an alkaloid (HHT) derived from a conifer tree.
Acute myeloid leukemia (AML) is not one disease but a group of hematopoietic neoplasms with varying genotypes, yet similar phenotypes. The cancer arises from hematopoietic stem cells that normally differentiate into myeloid cells such as granulocytes, monocytes, and erythrocytes.
A clinical trial targeting BCMA CAR-T cells with GSIs shows promising results for patients suffering from multiple myeloma.
Multiple myeloma (MM) is a plasma cell cancer that has affected an estimated 32,110 people in the US in 2019 according to the National Cancer Institute. About a half million people worldwide have this disease. Due to the progressive and mutational nature of MM, it remains difficult to treat successfully. Studies to better understand the mechanisms involved in MM progression are needed to inform what therapeutic approaches would best provide effective treatment for MM.
A Phase III clinical trial comparing hematopoietic stem cell transplants to immunomodulators is underway.
Multiple sclerosis (MS) is an autoimmune disease characterized by the destruction of the myelin sheath of nerve fibers. There is no cure for the condition, but there are a number of FDA-approved immunomodulators or disease-modifying therapies to reduce relapses and slow disease progression. Despite the availability of these drugs, their varying efficacy, adverse effects, and expense are significant concerns. Therefore, a means to safely and effectively control MS symptoms and progression is still under investigation.